AMLODIPINE BENZOATE
| Brand name | KATERZIA |
|---|---|
| Active ingredient | AMLODIPINE BENZOATE |
| Strength | EQ 1MG BASE/ML |
| Dosage form | SUSPENSION |
| Route | ORAL |
| Modality | Small molecule |
| FDA approval | July 2019 |
| Marketing status | RX |
| Patent | Expires | Type |
|---|---|---|
| 10799453 | April 2039 | product |
| 10695329 | October 2037 | product |
| 11471409 | October 2037 | use U-3448 |
| 12336984 | October 2037 | use U-3448 |
| 11918685 | October 2037 | use U-3448 |
| 11701326 | October 2037 | product |
| 11484498 | October 2037 | product |
| 10952998 | October 2037 | product |
| 12383498 | October 2037 | product |
| 11364230 | October 2037 | product |
| 10959991 | October 2037 | use U-158 |
| 12053461 | October 2037 | product |
| 10894039 | October 2037 | use U-185 |
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.